News • Pandemic prevention

German lab developed coronavirus detection method

Investigators at Hannover Medical School (MHH) in Germany have developed a molecular assay for detecting the novel coronavirus SARS-CoV-2 (previously 2019-nCoV) on the automated Panther Fusion system by Hologic.

The preclinical assay is described online in the Journal of Clinical Virology. “Rapid diagnosis is critical to combatting the spread of pandemics, and the Panther Fusion system is well suited to this purpose,” said Albert Heim, M.D, head of molecular diagnostics at MHH. “Using inactivated virus from cell cultures and commercially available control materials, we adapted two recently published PCR protocols to run on the Panther Fusion system. Our next step will be to validate our assay on clinical samples.”

blue gloved hand holding a plate well in a medical laboratory

© MHH/Karin Kaiser

The emerging SARS-coronavirus-2 (SARS-CoV-2) can cause severe respiratory tract infections (COVID-19) and has been declared a public health emergency by the WHO. “It’s extremely gratifying to see our instrument system being used to quickly develop a response to an urgent public health threat,” said Kevin Thornal, president of the Diagnostic Solutions division at Hologic. “We specifically designed Panther Fusion and Open Access functionality to give diagnostic lab customers maximum flexibility, both for their day-to-day needs and to respond quickly to emerging threats.”

The Open Access functionality on the Panther Fusion system allows accredited medical laboratories to design and validate laboratory developed tests (LDTs) to run on the fully automated, high-throughput platform. Laboratories can run their LDTs simultaneously with commercially available CE-IVD assays in a random access model, without waiting to batch tests. Users of Open Access are required to follow all applicable local requirements for their laboratory and users in developing and validating their own LDTs on the Panther Fusion system.

The assay described has not received CE-IVD certification in Europe or clearance from the Food and Drug Administration (FDA) in the United States.


Source: Hologic

06.03.2020

Read all latest stories

Related articles

Photo

Article • Digital breast tomosynthesis (DBT)

New EU recommendations for breast screening enhance opportunities for early detection

Mammography has been an essential imaging technology for breast cancer detection for decades. As the industry has continued to innovate, one advancement in mammography has particularly changed the…

Photo

Article • Hologic at ECR 2022

Painting a global picture of Women’s health

At the ECR 2022 congress in Vienna, Hologic went beyond just showcasing new systems for women’s health. Additional focus topics were the mitigation of the pandemic impact on screening programmes…

Photo

Sponsored • Women's health

Improving Workflow and Patient Care Through Innovation

Groundbreaking technologies have improved our ability to accurately diagnose breast cancer and reduce callbacks, focusing on compassionate care for patients as they move along their breast health…

Related products

Subscribe to Newsletter